Research Grants:
- 2004-2005: AIRC Research Grant, Ospedale Bellaria Bologna (FIRC: Italian Foundation for Cancer Research): Mechanisms of endocrine therapy resistance: estrogen receptor and epidermal growth factor receptor in breast cancer;
- 2013: 3-year Young Investigators Translational Research Grant “Alessandro Liberati”: Assessment of MGMT promoter methylation and clinical benefit from temozolomide-based therapy in Ewing sarcoma patients.
Clinical Research Experience:
- 2001: Visiting Research Fellow, Rockefeller University, New Yor;
- 2001: Clinical Observer, Memorial Sloan-Kettering Cancer Center, New York;
- 2003: Dompè Course, “Anemia in cancer patients” Karolinska Institute, Stockholm;
- 2006: ESMO Translational Research Unit Visit, Institute Gustave Roussy, Paris;
- 2007: 1° ESH/EBMT Course: “Blood and marrow transplantation Children”, Genova
Scientific and Medical Societies:
- 2003-present: American Society of Clinical Oncology (ASCO);
- 2004-present: Italian Society of Medical Oncology (AIOM);
- 2005-present: European Society for Medical oncology (ESMO).
Awards:
- 2002: “Evaristo Stefanelli” Award, Università di Bologna;
- 2003: “Lancet Travel Grant”, to attend the 39° ASCO Annual Meeting;
- 2004: FIRC-AIRC Grant;
- 2005, 2006, 2008, 2009: ASCO Foundation Abstract Merit Award”;
- 2005: Special correspondent Project, AMGEN, to attend the 41° ASCO Annual Meeting;
- 2006: “ESMO Translational Research Unit Visit Award”, Istituto Gustave Roussy;
- 2006: AIOM Best Abstract Award";
- 2010: ESMO Congress Travel Grant;
- 2014: ESMO Congress Travel Grant, Madrid, Spain.
Pubblications. Author of several papers (>45) on international scientific journals and author of 3 book chapters.
Clinical Protocol Experience (Phase II, role: sub-I):
- Pemetrexed (Alimta, ®Lilly) in metastatic osteosarcoma
- STI571 (Glivec, ®Novartis) in chondrosarcoma
- ET 743 (Yondelis, Pharmamar) neoadjuvant in sarcomas
- ET 743 (Yondelis, Pharmamar) metastatic sarcomas
- CP-751,871 (Pfizer) in metastatic Ewing sarcomas
- Denosumab (Amgen) in metastatic/unresectable GCT
- Lapatinib (Tyverb®) in advanced chordomas
- R1507 (Roche) in metastatic Ewing sarcomas
- Deforolimus (Ariad), in responding sarcomas
- IPI 926 (Infinity), in metastastic chondrosarcomas
- Zalypsis® (PM00104), in metastastic Ewing sarcoma
- Sorafenib/Everolimus in metastatic osteosarcoma
- NGR-hTNF in metastastatic soft tissue sarcoma
- ISG STS 10.01: targeted vs. untargeted STS adjuvant
- Morab-004 (Morphotek) in metastatic sarcoma